Efficacy and Safety of SGLT2 Inhibitors in Patients With Genetic Lipodystrophy: A Real‐Life Experience From a National Reference Network
Authors' conclusion
In a real-life setting, SGLT2i therapy is associated with improvement in HbA1c, body weight, blood pressure, hepatic parameters and albuminuria in patients with genetic lipodystrophy.
Study context
- Population
- Patients with familial partial lipodystrophy or congenital generalised lipodystrophy initiated on SGLT2i, French reference network PRISIS; 86% women57 FPLD, 2 CGL · or congenital generalised lipodystrophy 2
- Exposure
- SGLT2i: before initiation vs short-term and long-term follow-up
- Outcome
- HbA1c
- Follow-up
- Short-term (6-18 months) and long-term (latest )
Methodological detailsreal-life, national reference network (PRISIS)
- Real-life
- National reference network (PRISIS)
Main finding
As reported in the abstract
- Short-term vs Baseline: P < 0.01
- Long-term vs Baseline: P = 0.05
- No primary endpoint named
Observational data: associations, not effects.
Further findings
| Outcome | Baseline | Short-term | P value |
|---|---|---|---|
| Systolic blood pressure · short-termShort-term vs Baseline · median, mmHg | 130 (IQR 120–143.25) | 126 (IQR 120–137) | P < 0.05 |
| ALT · short-termShort-term vs Baseline · median, IU/L | 33 (IQR 23.5–44) | 30 (IQR 26–40) | 0.02 |
| GGT · short-termShort-term vs Baseline · median, IU/L | 44 (IQR 28.5–62.5) | 37 (IQR 27.85–45.5) | 0.02 |
| Liver stiffness · short-termShort-term vs Baseline | median 6.8 (IQR 5.9–11.8) kPa | median 5.8 (IQR 5–6.9) kPa | < 0.01 |
| DXA fat mass percentage · short-termShort-term vs Baseline · tended to decrease · median | 23.6 (IQR 18–29.3) | 20.8 (IQR 17.8–25.3) | P = 0.07 |
| Truncal-to-lower limb fat ratio · short-termShort-term vs Baseline · tended to decrease · median | 1.36 (IQR 1.18–1.50) | 1.17 (IQR 0.98–1.41) | P = 0.08 |
| Urinary albumin-to-creatinine ratio, when elevated at baseline (> 3 mg/mmol, n = 18)Short-term vs Baseline · follow-up time point not stated · median, mg/mmol | 10.8 (IQR 6.3–24.9) | 8.0 (IQR 2.8–14.4) | P = 0.02 |
- BMI · short-term and long-term · Long-term vs Baseline
- P < 0.001
Safety
- Treatment discontinuation, mainly due to vaginal mycoses
- 7%
- Serious adverse events
- 0
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Efficacy and Safety of SGLT2 Inhibitors in Patients With Genetic Lipodystrophy: A Real‐Life Experience From a National Reference Network. Diabetes Obes Metab. Published 19 August 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →